DELRAY BEACH, FL (Boca Post) (Copyright © 2025) — Delray Medical Center has joined an elite group of hospitals in Florida after successfully completing its first TRICvalve implantation for tricuspid regurgitation — a complex heart condition that can cause severe fatigue and fluid buildup.
The procedure conducted by Dr. Tilak Pasala Medical Director of Structural Heart Disease at the facility represents a major breakthrough for cardiovascular treatment in the area. According to the hospital, Delray is now one of just three sites statewide to perform the TRICvalve procedure.
The TRICvalve system offers a minimally invasive option for patients with severe tricuspid regurgitation (TR), a condition where the heart’s tricuspid valve fails to close properly, allowing blood to flow backward into the right atrium. The TRICvalve system delivers two self-expanding bioprosthetic valves through transcatheter procedures which enter the body through the superior and inferior vena cava (SVC and IVC).
The procedure enhances right heart performance and life quality while minimizing the dangers associated with surgical procedures. The treatment provides symptom relief to high-risk patients who experience swelling and congestion and shortness of breath.
The Delray Medical Center spokesperson announced the achievement through a statement after the procedure. “The organization provides TRICvalve advanced treatments to local patients who needed surgical options because they had no other choice.
The initiative is led by Dr. Tilak Pasala, MD, FACC, FSCAI, MBA, an expert with national recognition for his expertise in structural cardiology. Dr. Pasala dedicates his professional work to developing catheter-based treatments for complicated valve conditions while leading more than eight medical device research trials as principal investigator.
Before joining Delray Medical Center, Dr. Pasala held leadership roles at Hackensack University Medical Center in New Jersey and AdventHealth Orlando. He also served as an Associate Professor of Medicine at the Hackensack School of Medicine and directed one of the nation’s few dedicated Structural Heart Disease Fellowship programs.
His medical training took place at Case Western Reserve University/MetroHealth and the University of Utah and Hackensack University Medical Center which are recognized for developing cardiovascular innovation leaders.
“Every advancement like this brings us closer to transforming how we treat structural heart disease,” Dr. Pasala said in previous remarks about his work. “Our organization exists to provide safe and effective minimally invasive treatments which we make available to patients who need them most.
The Delray Medical Center reached a major achievement through its initial TRICvalve implantation which established its position as the leading center for complex cardiac treatment in the region.
